Description

Indication of Xeljanz (Tofacitinib INN )11mg

Xeljanz (Tofacitinib INN )11mg  is prescribed to address various inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

Pharmacology

Containing tofacitinib, TOCIT-XR Tablet acts as an inhibitor of Janus kinases (JAKs). These enzymes are pivotal in the signaling pathways of numerous cytokines and growth factors involved in inflammation. Tofacitinib’s inhibition of JAKs modulates immune responses, diminishes inflammation, and relieves symptoms linked with inflammatory disorders.

Dosage and Administration

The prescribed dosage of Xeljanz (Tofacitinib INN )11mg is contingent on the specific condition being treated and individual patient response. Typically administered orally once daily, the dosage may be adjusted by healthcare professionals based on patient factors and treatment progress.

Interaction

TOCIT-XR Tablet may interact with other medications, particularly those affecting the immune system or heightening infection risks. Concurrent usage with immunosuppressive agents or live vaccines may amplify immunosuppression and infection risks. Patients are advised to disclose all medications, supplements, and herbal products to their healthcare provider prior to initiating TOCIT-XR Tablet.

**Side Effects**

Common adverse effects of Xeljanz (Tofacitinib INN )11mgTablet may encompass upper respiratory tract infections, headaches, hypertension, elevated liver enzymes, and gastrointestinal disturbances. Although less frequent, severe adverse reactions like infections, gastrointestinal perforation, hepatotoxicity, and hypersensitivity reactions may occur. Patients should be closely monitored for any adverse effects during treatment.

**Precautions and Warnings**

Patients with a history of infections, pre-existing gastrointestinal disorders, hepatic impairment, or hypersensitivity to tofacitinib or its components should use Tofacitinib XR Tablet cautiously. Vigilant monitoring for signs of infection, liver function abnormalities, and other adverse reactions is advised during treatment.

Overdose Effects of Xeljanz (Tofacitinib INN )11mg

In instances of overdose, supportive care and symptomatic treatment should be promptly initiated. While limited information exists regarding tofacitinib overdose, management should be guided by clinical judgment and the patient’s condition. Close monitoring for adverse reactions and complications is imperative in cases of tofacitinib overdose.